治疗和监测乙酸性纤维炎的治疗和监测
Albert Selva-O'Callaghan1, Ernesto Trallero-Araguás2, Albert Gil-Vila1
1Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d'Hebron General Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Current treatment options in rheumatology
|March 21, 2025
概括
乙性带炎 (EF) 治疗缺乏标准指导方针. 目前的治疗包括免疫抑制剂和新兴生物药物,先进的成像技术有助于疾病监测.
科学领域:
- 类风湿病学 类风湿病学
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 乙酸性膜炎 (EF) 是一种罕见的炎症状况,导致皮肤硬化.
- 现有的EF管理指南有限,需要进一步研究.
研究的目的:
- 审查当前治疗策略和监测方法,以乙酸性带炎.
- 突出EF管理中需要标准化建议的需要.
主要方法:
- 对EF治疗和监测的当前文献的综述.
- 分析既定和新兴的治疗方式.
- 评估用于疾病评估的成像技术.
主要成果:
- 标准EF治疗包括葡萄糖皮质类药物和免疫抑制剂,用于耐火病例.
- 在病例报告中,生物药物,JAK抑制剂,抗IL5,IVIg和光聚变具有前景.
- 像MRI,PET/TC和POCUS这样的先进成像技术对于监测治疗反应非常有价值.
结论:
- 关于EF治疗和监测的高质量数据很少.
- 标准化定义和前性试验对于EF的基于证据的医学至关重要.
- 目前的管理依赖于可用的数据和专家经验.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
204
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
204
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Pulmonary Tuberculosis V
159
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
159
Pneumonia IV: Management
282
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
282
Cystic Fibrosis: Management
134
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
134
Pleural Effusion II: Symptoms and Management
144
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
144


